The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
Abstract
Purpose: To compare the long-term outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of known prognostic factors after treatment with R-CVP. Patients and Methods: Patients with previously untreated CD20-positive stage III/IV FL were randomly assigned to eight cycles of R-CVP (n = 159) or CVP alone (n = 162). The median follow-up period was 53 months. Results: The primary end point—time to treatment failure (TTF), which included patients without a response after four cycles as an event—was significantly prolonged in patients receiving R-CVP versus CVP (P < .0001). Improvements in all other end points, including overall and complete response rates (P < .0001), time to progression (TTP; P < .0001), response duration (P < .0001), time to next antilymphoma treatment (P < .0001), and overall survival (OS; P = .029; 4-year OS: 83% v 77%;) were achieved with R-CVP versus CVP alone. Univariate analyses demonstrated an improvement in TTP with R-CVP versus CVP irrespective of the Follicular Lymphoma International Prognostic Index (FLIPI) subgroup, the International Prognostic Index (IPI) subgroup, baseline histology, and the presence or absence of B symptoms or bulky disease. By multivariate analysis, FLIPI retains a strong predictive power for TTP in the presence of the trial treatment effect. Conclusion: Analysis of all outcome measures, including OS, confirm the benefit of adding R to CVP in the front-line treatment of FL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Follicular lymphoma international prognostic index
Solal-Celigny, P. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0036-3 · Cited by 1,339
Self-citationHiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Marcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
Self-citationFollicular Lymphoma International Prognostic Index
Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2003-12-4434 · Cited by 626
Self-citationSchulz, H., Bohlius, J. F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk152 · Cited by 362
Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma
Rohatiner, A. Z. S., Gregory, W. M., Peterson, B., Borden, E., Solal-Celigny, P., Hagenbeek, A., Fisher, R. I., Unterhalt, M., Arranz, R., Chisesi, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.146 · Cited by 170
Self-citationGhielmini, M., Rufibach, K., Salles, G., Leoncini-Franscini, L., Léger-Falandry, C., Cogliatti, S., Fey, M., Martinelli, G., Stahel, R., Lohri, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi320 · Cited by 166
Cited by
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Self-citationCarson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Casulo, C., Byrtek, M., Dawson, K. L., Zhou, X., Farber, C. M., Flowers, C. R., Hainsworth, J. D., Maurer, M. J., Cerhan, J. R., Link, B. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7534 · Cited by 850
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Self-citation
Metadata
- Authors
- Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J. V., Dmoszynska, A., Raposo, J. C., Offner, F. C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E., & Stein, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-10-01
- Volume
- 26
- Issue
- 28
- Pages
- 4579-4586
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2135321054
- Cited by
- 594
- References
- 9
- FWCI
- 30.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.